Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Apr;3(2):191-9.
doi: 10.2217/14796694.3.2.191.

Deubiquitinating enzymes as novel anticancer targets

Affiliations
Review

Deubiquitinating enzymes as novel anticancer targets

Benjamin Nicholson et al. Future Oncol. 2007 Apr.

Abstract

Tagging proteins with mono- or poly-ubiquitin is now recognized as a multifaceted and universal means of regulating cell growth and physiology. It does so by controlling the cellular lifetime of nearly all eukaryotic proteins and the cellular localization of many critical proteins. Enzymes of the ubiquitin pathway add (ligases) or remove (deubiquitinases [DUBs]) ubiquitin tags to or from their target proteins in a selective fashion. Similarly to the kinases and their corresponding phosphatases, ubiquitin ligases and DUBs have become actively studied molecular oncology targets for drug discovery. Approximately 79 functional DUBs exist in the human proteome, suggesting that selective intervention is a reasonable therapeutic objective, with the goal of downregulating or ablating oncogene products or, alternatively, upregulating or sparing tumor suppressors. In the following review, this fascinating class of regulatory enzymes will be described, and specific examples of DUBs that are viable targets for anticancer therapy will be considered.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Ubiquitin pathway showing ubiquitin conjugation (E1, E2 and E3) and DUB activities
In some cases, ubiquitin chain assembly factor (E4) has been shown to enhance the conjugation of ub to certain substrates (not shown). AMP: Adenosine monophosphate; DUB: Deubiquitinase; PPi: Phosphate; ub: Ubiquitin.
Figure 2
Figure 2. USP7 preferentially deubiquitinates Hdm2
Relative to p53, USP7 has a higher affinity for Hdm2, thus USP7 preferentially deubiquitinates Hdm2, preventing Hdm2 from inducing its own degradation due to autoubiquitination. Subsequently, Hdm2 ubiquitinates p53, which is degraded by the proteasome. An inhibitor of USP7 is predicted to promote the degradation of Hdm2 and therefore abrogate the degradation of p53 by the ubiquitin proteosome system. ub: Ubiquitin; USP: Ubiquitin-specific protease.
Figure 3
Figure 3. Model for inhibition of USP2a
An inhibitor of USP2a is predicted to promote the degradation of FAS, thus abrogating the antiapoptotic activity of FAS. FAS: Fatty acid synthase; ub: Ubiquitin; USP: Ubiquitin-specific protease.

Similar articles

Cited by

References

    1. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425–479. - PubMed
    2. •• Complete overview of the ubiquitin conjugation and deconjugation system.

    1. Welchman RL, Gordon C, Mayer RJ. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol. 2005;6:599–609. - PubMed
    1. Amerik AY, Hochstrasser M. Mechanism and function of deubiquitinating enzymes. Biochim Biophys Acta. 2004;1695:189–207. - PubMed
    2. • Comprehensive review of deubiquitnases (DUBs).

    1. Nijman SM, Luna-Vargas MP, Velds A, et al. A genomic and functional inventory of deubiquitinating enzymes. Cell. 2005;123:773–786. - PubMed
    2. • Review of DUBs including a genomic perspective.

    1. Cheng J, Bawa T, Lee P, Gong L, Yeh ET. Role of desumoylation in the development of prostate cancer. Neoplasia. 2006;8:667–676. - PMC - PubMed

Publication types

MeSH terms